---
title: "JIUDIAN PHARMACEUTICAL: Acquired the Drug Clinical Trial Approval Notice through Assignment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253952507.md"
description: "JIUDIAN PHARMACEUTICAL announced that the company has acquired all developed results and corresponding intellectual property rights of JIJ02 gel owned by Chengdu Peide Biopharmaceutical Co., Ltd. for 90 million yuan, and has signed the \"Technology Transfer Contract.\" The drug name is JIJ02 gel, registered as a Class 1 chemical drug, with the intended indication for common acne. The company's acquisition of the clinical trial approval notice for this drug will not have a significant impact on the company's financial condition and operating performance"
datetime: "2025-08-21T09:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253952507.md)
  - [en](https://longbridge.com/en/news/253952507.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253952507.md)
generator: "portal-rs"
---

# JIUDIAN PHARMACEUTICAL: Acquired the Drug Clinical Trial Approval Notice through Assignment

JIUDIAN PHARMACEUTICAL announced that the company has acquired all developed results and corresponding intellectual property rights of JIJ02 gel from Chengdu Peide Biopharmaceutical Co., Ltd. for 90 million yuan, and signed the "Technology Transfer Contract." The drug name is JIJ02 gel, registered as Class 1 chemical drug, with the intended indication for common acne. The company's acquisition of the clinical trial approval notice for this drug will not have a significant impact on the company's financial condition and operating performance

### Related Stocks

- [300705.CN](https://longbridge.com/en/quote/300705.CN.md)

## Related News & Research

- [Under-eye patches aren’t just skincare anymore. Now, they're a flex.](https://longbridge.com/en/news/296597484.md)
- [11:00 ETLumenStim se prepara para lanzar en Kickstarter su sistema de blanqueamiento dental de última generación](https://longbridge.com/en/news/296633006.md)
- [08:38 ETThe 2027 NAMM Show Announces Global Five-Day Celebration of Music, Product Innovation and Industry Leadership](https://longbridge.com/en/news/296229778.md)
- [14:18 ETVascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins](https://longbridge.com/en/news/296388379.md)
- [3 Ways to Slay: CurlyMe 3-In-1 Half Wig Sparks a New Hair Revolution](https://longbridge.com/en/news/296447697.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**